RESVERATROL: A MULTIFACETED NATURAL COMPOUND WITH THERAPEUTIC POTENTIAL
DOI:
https://doi.org/10.22159/ijpps.2026v18i1.57113Keywords:
Resveratrol, Polyphenol, Antioxidant, Cardioprotection, Neuroprotection, Anticancer, Anti-inflammatory, Anti-aging cream, bioavailabilityAbstract
Resveratrol, a plant-derived polyphenol abundant in grapes, berries, peanuts, and red wine, has been the subject of intense scientific exploration for more than three decades. First associated with the French Paradox, it is now widely studied for its ability to influence multiple biological pathways that underlie chronic disease and aging. Experimental evidence shows that resveratrol reduces oxidative stress, modulates inflammatory cascades, improves mitochondrial function, and regulates cell survival and metabolism. Through these actions, it exerts antioxidant, anti-inflammatory, cardioprotective, anticancer, neuroprotective, antidiabetic, hepatoprotective, antimicrobial, and anti-aging effects. While laboratory and animal studies provide compelling support, outcomes from human trials remain variable, reflecting challenges such as poor bioavailability, rapid metabolism, and differences in study design. Recent innovations including nanoparticle based carriers, synthetic analogs, and synergistic formulations are being developed to enhance its stability and clinical utility. Resveratrol is not a miracle cure, but rather a promising candidate for adjunct therapy, underscoring the potential of natural compounds to complement conventional medicine pending further clinical validation. Its journey underscores the need for rigorous, long-term, and well controlled clinical studies to establish effective doses, safety profiles, and therapeutic applications. By bridging traditional phytotherapy and modern translational science, resveratrol continues to inspire both researchers and clinicians in the search for holistic approaches to health and disease management.
Downloads
References
1. Wang DG, Liu WY, Chen GT. A simple method for the isolation and purification of resveratrol from Polygonum cuspidatum. J Pharm Anal. 2013 Aug;3(4):241-7. doi: 10.1016/j.jpha.2012.12.001, PMID 29403824.
2. Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French paradox revisited. Front Pharmacol. 2012 Jul 17;3:141. doi: 10.3389/fphar.2012.00141, PMID 22822401.
3. Orallo F. Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr Med Chem. 2006;13(1):87-98. doi: 10.2174/092986706775197962, PMID 16457641.
4. Thiel G, Rossler OG. Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors. Pharmacol Res. 2017 Mar;117:166-76. doi: 10.1016/j.phrs.2016.12.029, PMID 28012964.
5. Fremont L. Biological effects of resveratrol. Life Sci. 2000 Jan;66(8):663-73. doi: 10.1016/S0024-3205(99)00410-5, PMID 10680575.
6. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006 Jun 26;5(6):493-506. doi: 10.1038/nrd2060, PMID 16732220.
7. Kulkarni SS, Canto C. The molecular targets of resveratrol. Biochim Biophys Acta. 2015 Jun;1852(6):1114-23. doi: 10.1016/j.bbadis.2014.10.005, PMID 25315298.
8. Gulcin I. Antioxidant properties of resveratrol: a structure-activity insight. Innov Food Sci Emerg Technol. 2010 Jan;11(1):210-8. doi: 10.1016/j.ifset.2009.07.002.
9. Walle T. Bioavailability of resveratrol. Ann NY Acad Sci. 2011 Jan 24;1215(1):9-15. doi: 10.1111/j.1749-6632.2010.05842.x, PMID 21261636.
10. Chimento A, De Amicis F, Sirianni R, Sinicropi MS, Puoci F, Casaburi I. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int J Mol Sci. 2019 Mar 19;20(6):1381. doi: 10.3390/ijms20061381, PMID 30893846.
11. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release. 2012 Mar;158(2):182-93. doi: 10.1016/j.jconrel.2011.09.083, PMID 21978644.
12. Machado ND, Fernandez MA, Diaz DD. Recent strategies in resveratrol delivery systems. ChemPlusChem. 2019 Jul 10;84(7):951-73. doi: 10.1002/cplu.201900267, PMID 31943987.
13. Najafiyan B, Bokaii Hosseini Z, Esmaelian S, Firuzpour F, Rahimipour Anaraki S, Kalantari L. Unveiling the potential effects of resveratrol in lung cancer treatment: mechanisms and nanoparticle-based drug delivery strategies. Biomed Pharmacother. 2024 Mar;172:116207. doi: 10.1016/j.biopha.2024.116207, PMID 38295754.
14. Isailovic BD, Kostic IT, Zvonar A, Dordevic VB, Gasperlin M, Nedovic VA. Resveratrol-loaded liposomes produced by different techniques. Innov Food Sci Emerg Technol. 2013 Jul;19:181-9. doi: 10.1016/j.ifset.2013.03.006.
15. Chen H, Tuck T, Ji X, Zhou X, Kelly G, Cuerrier A. Quality assessment of Japanese knotweed (Fallopia japonica) grown on Prince Edward Island as a source of resveratrol. J Agric Food Chem. 2013 Jul 3;61(26):6383-92. doi: 10.1021/jf4019239, PMID 23742076.
16. Sales JM, Resurreccion AV. Resveratrol in peanuts. Crit Rev Food Sci Nutr. 2014 Jan 17;54(6):734-70. doi: 10.1080/10408398.2011.606928, PMID 24345046.
17. Hasan M, Bae H. An overview of stress-induced resveratrol synthesis in grapes: perspectives for resveratrol-enriched grape products. Molecules. 2017 Feb 14;22(2):294. doi: 10.3390/molecules22020294, PMID 28216605.
18. Hangun Balkir Y, McKenney ML. Determination of antioxidant activities of berries and resveratrol. Green Chem Lett Rev. 2012 Jun;5(2):147-53. doi: 10.1080/17518253.2011.603756.
19. Aldred D, Cairns Fuller V, Magan N. Environmental factors affect efficacy of some essential oils and resveratrol to control growth and ochratoxin a production by Penicillium verrucosum and Aspergillus westerdijkiae on wheat grain. J Stored Prod Res. 2008;44(4):341-6. doi: 10.1016/j.jspr.2008.03.004.
20. Geana EI, Dinca OR, Ionete RE, Artem V, Niculescu VC. Monitoring trans-resveratrol in grape berry skins during ripening and in corresponding wines by HPLC. Food Technol Biotechnol. 2015 Mar 30;53(1):73-80. doi: 10.17113/ftb.53.01.15.3762, PMID 27904334.
21. Lachman J, Sulc M, Hejtmankova A, Pivec V, Orsak M. Content of polyphenolic antioxidants and trans-resveratrol in grapes of different varieties of grapevine (Vitis vinifera L.). Hortic Sci. 2004;31(2):63-9. doi: 10.17221/3794-HORTSCI.
22. Taquichiri M, Ayarde R, Gutierrez P, Bustos AS, Paredes C, Callisaya JC. High levels of resveratrol in grapes cultivated at high altitude valleys in Bolivia. Int J Fruit Sci. 2014 Jul 3;14(3):311-26. doi: 10.1080/15538362.2013.819748.
23. Hurst WJ, Glinski JA, Miller KB, Apgar J, Davey MH, Stuart DA. Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products. J Agric Food Chem. 2008 Sep 24;56(18):8374-8. doi: 10.1021/jf801297w, PMID 18759443.
24. Paradiso A, D Amico L, Nicoletti I, Santino A, De Gara L, Giovinazzo G. Resveratrol biosynthesis up-regulates the ascorbate/glutathione pathway in transgenic tomato fruit. J Plant Biochem Physiol. 2013;1(2):2-7. doi: 10.4172/jpbp.1000105.
25. Niu J, Hou Z, Ou Z, Hui W. Comparative study of effects of resveratrol, 1-MCP and DPA treatments on postharvest quality and superficial scald of ‘Starkrimson’ apples. Sci Hortic. 2018 Oct;240:516-21. doi: 10.1016/j.scienta.2018.06.037.
26. Francini A, Sebastiani L. Phenolic compounds in apple (malus x domestica Borkh.): compounds characterization and stability during postharvest and after processing. Antioxidants (Basel). 2013 Sep 18;2(3):181-93. doi: 10.3390/antiox2030181, PMID 26784345.
27. Xu Y, Fang M, Li X, Wang D, Yu L, Ma F. Contributions of common foods to resveratrol intake in the Chinese diet. Foods. 2024 Apr 21;13(8):1267. doi: 10.3390/foods13081267, PMID 38672939.
28. Serra AT, Matias AA, Frade RF, Duarte RO, Feliciano RP, Bronze MR. Characterization of traditional and exotic apple varieties from Portugal. Part 2 – Antioxidant and antiproliferative activities. J Funct Foods. 2010 Jan;2(1):46-53. doi: 10.1016/j.jff.2009.12.005.
29. Shrikanta A, Kumar A, Govindaswamy V. Resveratrol content and antioxidant properties of underutilized fruits. J Food Sci Technol. 2015 Jan;52(1):383-90. doi: 10.1007/s13197-013-0993-z, PMID 25593373.
30. Kurita S, Kashiwagi T, Ebisu T, Shimamura T, Ukeda H. Content of resveratrol and glycoside and its contribution to the antioxidative capacity of Polygonum cuspidatum (Itadori) harvested in Kochi. Biosci Biotechnol Biochem. 2014 Mar 4;78(3):499-502. doi: 10.1080/09168451.2014.890032, PMID 25036841.
31. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res. 2010 Nov 15;70(22):9003-11. doi: 10.1158/0008-5472.CAN-10-2364, PMID 20935227.
32. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA. Resveratrol modulates drug and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep 1;3(9):1168-75. doi: 10.1158/1940-6207.CAPR-09-0155, PMID 20716633.
33. Tome Carneiro J, Gonzalvez M, Larrosa M, Yanez Gascon MJ, Garcia Almagro FJ, Ruiz Ros JA. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012 Aug;110(3):356-63. doi: 10.1016/j.amjcard.2012.03.030, PMID 22520621.
34. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health a comprehensive review of Human Clinical Trials. Mol Nutr Food Res. 2011 Aug 20;55(8):1129-41. doi: 10.1002/mnfr.201100143, PMID 21688389.
35. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv. 2014 Aug 15;11(8):1285-98. doi: 10.1517/17425247.2014.919253, PMID 24830814.
36. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin Montalvo A, North BJ. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012 May;15(5):675-90. doi: 10.1016/j.cmet.2012.04.003, PMID 22560220.
37. Pouremamali F, Pouremamali A, Dadashpour M, Soozangar N, Jeddi F. An update of Nrf2 activators and inhibitors in cancer prevention/promotion. Cell Commun Signal. 2022 Dec 30;20(1):100. doi: 10.1186/s12964-022-00906-3, PMID 35773670.
38. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M. Antihyperglycemic effects of short-term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267. doi: 10.1155/2013/851267, PMID 24073011.
39. Zhou DD, Luo M, Huang SY, Saimaiti A, Shang A, Gan RY. Effects and mechanisms of resveratrol on aging and age-related diseases. Oxid Med Cell Longev. 2021 Jan 12;2021(1):9932218. doi: 10.1155/2021/9932218, PMID 34336123.
40. Csiszar A. Anti‐inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann NY Acad Sci. 2011 Jan 24;1215(1):117-22. doi: 10.1111/j.1749-6632.2010.05848.x, PMID 21261649.
41. Meng T, Xiao D, Muhammed A, Deng J, Chen L, He J. Anti-inflammatory action and mechanisms of resveratrol. Molecules. 2021 Jan 5;26(1):229. doi: 10.3390/molecules26010229, PMID 33466247.
42. Ma C, Wang Y, Dong L, Li M, Cai W. Anti-inflammatory effect of resveratrol through the suppression of NF-κB and JAK/STAT signaling pathways. Acta Biochim Biophys Sin (Shanghai). 2015 Mar 1;47(3):207-13. doi: 10.1093/abbs/gmu135, PMID 25651848.
43. Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta. 2013 Oct;1832(10):1723-33. doi: 10.1016/j.bbadis.2013.05.018, PMID 23707558.
44. Simental Mendia LE, Guerrero Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: a randomized double-blind placebo-controlled trial. Nutrition. 2019 Feb;58:7-10. doi: 10.1016/j.nut.2018.06.015, PMID 30278430.
45. Xia N, Forstermann U, Li H. Resveratrol and endothelial nitric oxide. Molecules. 2014 Oct 9;19(10):16102-21. doi: 10.3390/molecules191016102, PMID 25302702.
46. Ojha R, Pranesh K, Bhavin V. Randomized active controlled clinical study to evaluate efficacy and safety of resveratrol as an adjuvant therapy in patients with hypertension. Asian J Pharm Clin Res. 2016 Jan 1;10(1):376. doi: 10.22159/ajpcr.2017.v10i1.15603.
47. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783-840. PMID 15517885.
48. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009 Jun;486(2):95-102. doi: 10.1016/j.abb.2009.01.018, PMID 19514131.
49. Xie Y, Wang Y, Xiang W, Wang Q, Cao Y. Molecular mechanisms of the action of myricetin in cancer. Mini Rev Med Chem. 2020;20(2):123-33. doi: 10.2174/1389557519666191018112756, PMID 31648635.
50. Thongsom S, Racha S, Petsri K, Ei ZZ, Visuttijai K, Moriue S. Structural modification of resveratrol analogue exhibits anticancer activity against lung cancer stem cells via suppression of Akt signaling pathway. BMC Complement Med Ther. 2023 Jun 3;23(1):183. doi: 10.1186/s12906-023-04016-6, PMID 37270520.
51. Innets B, Thongsom S, Petsri K, Racha S, Yokoya M, Moriue S. Akt/mTOR targeting activity of resveratrol derivatives in non-small lung cancer. Molecules. 2022 Nov 27;27(23):8268. doi: 10.3390/molecules27238268, PMID 36500361.
52. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011 Aug;106(3):383-9. doi: 10.1017/S0007114511000316, PMID 21385509.
53. Zhu P, Jin Y, Sun J, Zhou X. The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis. Front Endocrinol (Lausanne). 2025 Jan 13;15:1463027. doi: 10.3389/fendo.2024.1463027, PMID 39872318.
54. Szkudelski T, Szkudelska K. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 2015 Jun;1852(6):1145-54. doi: 10.1016/j.bbadis.2014.10.013, PMID 25445538.
55. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O Moore Sullivan TM, Lee P. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2092-103.e1. doi: 10.1016/j.cgh.2014.02.024, PMID 24582567.
56. Tejada S, Capo X, Mascaro CM, Monserrat Mesquida M, Quetglas Llabres MM, Pons A. Hepatoprotective effects of resveratrol in non-alcoholic fatty live disease. Curr Pharm Des. 2021 Sep 1;27(22):2558-70. doi: 10.2174/1381612826666200417165801, PMID 32303170.
57. Jia R, Li Y, Cao L, Du J, Zheng T, Qian H. Antioxidative anti-inflammatory and hepatoprotective effects of resveratrol on oxidative stress-induced liver damage in tilapia (Oreochromis niloticus). Comp Biochem Physiol C Toxicol Pharmacol. 2019 Jan;215:56-66. doi: 10.1016/j.cbpc.2018.10.002, PMID 30336289.
58. Gezer A, Ustundag H, Mendil AS, Bedir G, Duysak L. Hepatoprotective effects of resveratrol on α-amanitin-induced liver toxicity in rats. Toxicon. 2024 Aug;247:107855. doi: 10.1016/j.toxicon.2024.107855, PMID 38996975.
59. Albani D, Polito L, Signorini A, Forloni G. Neuroprotective properties of resveratrol in different neurodegenerative disorders. BioFactors. 2010 Sep 16;36(5):370-6. doi: 10.1002/biof.118, PMID 20848560.
60. Bastianetto S, Menard C, Quirion R. Neuroprotective action of resveratrol. Biochim Biophys Acta. 2015 Jun;1852(6):1195-201. doi: 10.1016/j.bbadis.2014.09.011, PMID 25281824.
61. Tresguerres IF, Tamimi F, Eimar H, Barralet J, Torres J, Blanco L. Resveratrol as anti-aging therapy for age-related bone loss. Rejuvenation Res. 2014 Oct;17(5):439-45. doi: 10.1089/rej.2014.1551, PMID 24956408.
62. De La Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005 May;49(5):405-30. doi: 10.1002/mnfr.200500022, PMID 15832402.
63. Wang W, Zhang LM, Guo C, Han JF. Resveratrol promotes osteoblastic differentiation in a rat model of postmenopausal osteoporosis by regulating autophagy. Nutr Metab (Lond). 2020 Dec 16;17(1):29. doi: 10.1186/s12986-020-00449-9, PMID 32322287.
64. Li Q, Yang G, Xu H, Tang S, Lee WY. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2021 Dec 22;21(1):214. doi: 10.1186/s12906-021-03381-4, PMID 34420523.
65. Vestergaard M, Ingmer H. Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents. 2019 Jun;53(6):716-23. doi: 10.1016/j.ijantimicag.2019.02.015, PMID 30825504.
66. Karamese M, Dicle Y. The antibacterial and antibiofilm activities of resveratrol on gram-positive and gram-negative bacteria. Kafkas J Med Sci. 2022;12(3):201-6. doi: 10.5505/kjms.2022.76743.
67. Ratz Lyko A, Arct J. Resveratrol as an active ingredient for cosmetic and dermatological applications: a review. J Cosmet Laser Ther. 2019 Feb 17;21(2):84-90. doi: 10.1080/14764172.2018.1469767, PMID 29737899.
68. Mascarenhas Melo F, Araujo A, Rodrigues M, Mathur A, Goncalves M, Tanwar K. Dermatological bioactivities of resveratrol and nanotechnology strategies to boost its efficacy an updated review. Cosmetics. 2023 Apr 24;10(3):68. doi: 10.3390/cosmetics10030068.
69. Kitada M, Koya D. Renal protective effects of resveratrol. Oxid Med Cell Longev. 2013;2013:568093. doi: 10.1155/2013/568093, PMID 24379901.
70. Dos Santos AB, Santos Terra J, Carletti JV, Deckmann I, Gottfried C. Molecular alterations in ferroptosis and the effects of resveratrol: a systematic review. J Biochem Mol Toxicol. 2025 Jul 30;39(7):e70384. doi: 10.1002/jbt.70384, PMID 40586281.
71. Murcia MA, Martinez Tome M. Antioxidant activity of resveratrol compared with common food additives. J Food Prot. 2001 Mar;64(3):379-84. doi: 10.4315/0362-028X-64.3.379, PMID 11252483.
72. Martins LA, Coelho BP, Behr G, Pettenuzzo LF, Souza IC, Moreira JC. Resveratrol induces pro-oxidant effects and time-dependent resistance to cytotoxicity in activated hepatic stellate cells. Cell Biochem Biophys. 2014 Mar 21;68(2):247-57. doi: 10.1007/s12013-013-9703-8, PMID 23793960.
73. Zhang J, Fu Q, Wang Y, Mu Y, Ren H, Xue L. Resveratrol alleviates oxidative stress, inflammatory cytokine expression and apoptosis induced by nanoplastics in the hemocytes of abalone (Haliotis discus hannai). Aquac rep. Aquacult Rep. 2025 Sep;43:102983. doi: 10.1016/j.aqrep.2025.102983.
74. Yang M, Shen Y, Zhao S, Zhang R, Dong W, Lei X. Protective effect of resveratrol on mitochondrial biogenesis during hyperoxia-induced brain injury in neonatal pups. BMC Neurosci. 2023 Apr 25;24(1):27. doi: 10.1186/s12868-023-00797-1, PMID 37098490.
75. Wu SK, Wang L, Wang F, Zhang J. Resveratrol improved mitochondrial biogenesis by activating SIRT1/PGC-1α signal pathway in SAP. Sci Rep. 2024 Oct 31;14(1):26216. doi: 10.1038/s41598-024-76825-9, PMID 39482340.
76. Shaito A, Al Mansoob M, Ahmad SM, Haider MZ, Eid AH, Posadino AM. Resveratrol mediated regulation of mitochondria biogenesis associated pathways in neurodegenerative diseases: molecular insights and potential therapeutic applications. Curr Neuropharmacol. 2023 May;21(5):1184-201. doi: 10.2174/1570159X20666221012122855, PMID 36237161.
77. Brown K, Theofanous D, Britton RG, Aburido G, Pepper C, Sri Undru S. Resveratrol for the management of human health: how far have we come? A systematic review of resveratrol clinical trials to highlight gaps and opportunities. Int J Mol Sci. 2024 Jan 6;25(2):747. doi: 10.3390/ijms25020747, PMID 38255828.
78. Li J, Koonyosying P, Korsieporn W, Paradee N, Hutachok N, Xu H. Deferiprone resveratrol hybrid attenuates iron accumulation oxidative stress and antioxidant defenses in iron-loaded human Huh7 hepatic cells. Front Mol Biosci. 2024 Mar 20;11:1364261. doi: 10.3389/fmolb.2024.1364261, PMID 38572444.
79. Kontoghiorghes GJ. New approaches and strategies for the repurposing of iron chelating/antioxidant drugs for diseases of free radical pathology in medicine. Antioxidants (Basel). 2025 Aug 10;14(8):982. doi: 10.3390/antiox14080982, PMID 40867878.
80. Pal K, Raghuram GV, Dsouza J, Shinde S, Jadhav V, Shaikh A. A pro-oxidant combination of resveratrol and copper down-regulates multiple biological hallmarks of ageing and neurodegeneration in mice. Sci Rep. 2022 Oct 14;12(1):17209. doi: 10.1038/s41598-022-21388-w, PMID 36241685.
81. Ahmad A, Syed FA, Singh S, Hadi SM. Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. Toxicol Lett. 2005 Oct;159(1):1-12. doi: 10.1016/j.toxlet.2005.04.001, PMID 15913925.
82. Farhan M, Rizvi A. Understanding the prooxidant action of plant polyphenols in the cellular microenvironment of malignant cells: role of copper and therapeutic implications. Front Pharmacol. 2022 Jun 20;13:929853. doi: 10.3389/fphar.2022.929853, PMID 35795551.
83. Gu XS, Wang ZB, Ye Z, Lei JP, Li L, Su DF. Resveratrol an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet Mol Res. 2014;13(1):323-35. doi: 10.4238/2014.January.17.17, PMID 24535859.
84. Bonnefont Rousselot D. Resveratrol and cardiovascular diseases. Nutrients. 2016 May 2;8(5):250. doi: 10.3390/nu8050250, PMID 27144581.
85. Bagul PK, Deepthi N, Sultana R, Banerjee SK. Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. J Nutr Biochem. 2015 Nov;26(11):1298-307. doi: 10.1016/j.jnutbio.2015.06.006, PMID 26298192.
86. Dyck GJ, Raj P, Zieroth S, Dyck JR, Ezekowitz JA. The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review. Int J Mol Sci. 2019 Feb 19;20(4):904. doi: 10.3390/ijms20040904, PMID 30791450.
87. Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017 Dec 1;18(12):2589. doi: 10.3390/ijms18122589, PMID 29194365.
88. Yang Q, Meng D, Zhang Q, Wang J. Advances in the role of resveratrol and its mechanism of action in common gynecological tumors. Front Pharmacol. 2024 Jul 17;15:1417532. doi: 10.3389/fphar.2024.1417532, PMID 39086397.
89. Song B, Wang W, Tang X, Goh RM, Thuya WL, Ho PC. Inhibitory potential of resveratrol in cancer metastasis: from biology to therapy. Cancers (Basel). 2023 May 14;15(10):2758. doi: 10.3390/cancers15102758, PMID 37345095.
90. Ferraresi A, Thongchot S, Isidoro C. Resveratrol promotes self-digestion to put cancer to sleep. J Cancer Prev. 2024 Mar 30;29(1):1-5. doi: 10.15430/JCP.24.001, PMID 38567110.
91. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res. 2010 Nov 15;70(22):9003-11. doi: 10.1158/0008-5472.CAN-10-2364, PMID 20935227.
92. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010 Oct 1;70(19):7392-9. doi: 10.1158/0008-5472.CAN-10-2027, PMID 20841478.
93. Xiao X, Wu X, Li W, You F, Guo J. Therapeutic effects and safety of resveratrol for lung cancer: an updated preclinical systematic review and meta-analysis. Front Nutr. 2025 Aug 29;12:1644538. doi: 10.3389/fnut.2025.1644538, PMID 40948874.
94. Varoni EM, Lo Faro AF, Sharifi Rad J, Iriti M. Anticancer molecular mechanisms of resveratrol. Front Nutr. 2016 Apr 12;3:8. doi: 10.3389/fnut.2016.00008, PMID 27148534.
95. Kohandel Z, Darrudi M, Naseri K, Samini F, Aschner M, Pourbagher Shahri AM. The role of resveratrol in aging and senescence: a focus on molecular mechanisms. Curr Mol Med. 2024 Jul;24(7):867-75. doi: 10.2174/1566524023666230602162949, PMID 37278035.
96. Kim EN, Lim JH, Kim MY, Ban TH, Jang IA, Yoon HE. Resveratrol an Nrf2 activator ameliorates aging-related progressive renal injury. Aging. 2018 Jan 11;10(1):83-99. doi: 10.18632/aging.101361, PMID 29326403.
97. Novelle MG, Wahl D, Dieguez C, Bernier M, De Cabo R. Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev. 2015 May;21:1-15. doi: 10.1016/j.arr.2015.01.002, PMID 25625901.
98. Timmers S, Konings E, Bilet L, Houtkooper RH, Van De Weijer T, Goossens GH. Calorie restriction-like effects of 30 d of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 Nov;14(5):612-22. doi: 10.1016/j.cmet.2011.10.002, PMID 22055504.
99. De Ligt M, Bruls YM, Hansen J, Habets MF, Havekes B, Nascimento EB. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first-degree relatives of patients with type 2 diabetes. Mol Metab. 2018 Jun;12:39-47. doi: 10.1016/j.molmet.2018.04.004, PMID 29706321.
100. Franco FN, Arrieta OA, De Mello Silva B, Aragao MM, Nagem RA, De Araujo GR. Nrf2 cell signaling pathway is responsible for the antioxidant effect of resveratrol in aging. Geriatr Gerontol Int. 2024 Sep 8;24(9):954-61. doi: 10.1111/ggi.14939, PMID 39118439.
101. Alesci A, Nicosia N, Fumia A, Giorgianni F, Santini A, Cicero N. Resveratrol and immune cells: a link to improve human health. Molecules. 2022 Jan 10;27(2):424. doi: 10.3390/molecules27020424, PMID 35056739.
102. Turner RS, Thomas RG, Craft S, Van Dyck CH, Mintzer J, Reynolds BA. A randomized double-blind placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20;85(16):1383-91. doi: 10.1212/WNL.0000000000002035, PMID 26362286.
103. Lopez MS, Dempsey RJ, Vemuganti R. Resveratrol neuroprotection in stroke and traumatic CNS injury. Neurochem Int. 2015 Oct;89:75-82. doi: 10.1016/j.neuint.2015.08.009, PMID 26277384.
104. Shin JA, Lee H, Lim YK, Koh Y, Choi JH, Park EM. Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. J Neuroimmunol. 2010 Oct;227(1-2):93-100. doi: 10.1016/j.jneuroim.2010.06.017, PMID 20655115.
105. Komorowska J, Wątroba M, Bednarzak M, Grabowska AD, Szukiewicz D. Anti-inflammatory action of resveratrol in the central nervous system in relation to glucose concentration-an in vitro study on a blood–brain barrier model. Int J Mol Sci. 2024 Mar 7;25(6):3110. doi: 10.3390/ijms25063110, PMID 38542084.
106. Mathew LS, Marathe A, Aman A, Vats A, Joy T, Rao YL. Bridging the molecular and clinical aspects of resveratrol in Alzheimer’s disease: a review. 3 Biotech. 2025 Sep 6;15(9):284. doi: 10.1007/s13205-025-04451-x, PMID 40777747.
107. Su CF, Jiang L, Zhang XW, Iyaswamy A, Li M. Resveratrol in rodent models of Parkinson’s disease: a systematic review of experimental studies. Front Pharmacol. 2021 Apr 22;12:644219. doi: 10.3389/fphar.2021.644219, PMID 33967780.
108. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol. 2010 Sep;78(3):466-77. doi: 10.1124/mol.110.064535, PMID 20554604.
109. Cebrian R, Li Q, Penalver P, Belmonte Reche E, Andres Bilbao M, Lucas R. Chemically tuning resveratrol for the effective killing of gram-positive pathogens. J Nat Prod. 2022 Jun 24;85(6):1459-73. doi: 10.1021/acs.jnatprod.1c01107, PMID 35621995.
110. Houille B, Papon N, Boudesocque L, Bourdeaud E, Besseau S, Courdavault V. Antifungal activity of resveratrol derivatives against candida species. J Nat Prod. 2014 Jul 25;77(7):1658-62. doi: 10.1021/np5002576, PMID 25014026.
111. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, De Lucia AL. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999 Oct;43(3):145-55. doi: 10.1016/S0166-3542(99)00042-X, PMID 10551373.
112. Annunziata G, Maisto M, Schisano C, Ciampaglia R, Narciso V, Tenore GC. Resveratrol as a novel anti-herpes simplex virus nutraceutical agent: an overview. Viruses. 2018 Sep 3;10(9):473. doi: 10.3390/v10090473, PMID 30177661.
113. Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F. Inhibition of influenza a virus replication by resveratrol. J Infect Dis. 2005 May 15;191(10):1719-29. doi: 10.1086/429694, PMID 15838800.
114. Lee S, Yoon KD, Lee M, Cho Y, Choi G, Jang H. Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. Br J Pharmacol. 2016 Jan 25;173(1):191-211. doi: 10.1111/bph.13358, PMID 26445091.
115. Van Brummelen R, Van Brummelen AC. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 a formulator’s perspective. Biomed Pharmacother. 2022 Apr;148:112767. doi: 10.1016/j.biopha.2022.112767, PMID 35240527.
116. Lagouge M, Argmann C, Gerhart Hines Z, Meziane H, Lerin C, Daussin F. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006 Dec 15;127(6):1109-22. doi: 10.1016/j.cell.2006.11.013, PMID 17112576.
117. Liu X, Gu X, Zhang J, Li X, Wei X, Jiang S. Resveratrol delays the progression of diabetic nephropathy through multiple pathways: a dose-response meta-analysis based on animal models. J Diabetes. 2024 Sep 12;16(9):e13608. doi: 10.1111/1753-0407.13608, PMID 39264004.
118. Camins A, Junyent F, Verdaguer E, Beas Zarate C, Rojas Mayorquin AE, Ortuno-Sahagun D. Resveratrol: an antiaging drug with potential therapeutic applications in treating diseases. Pharmaceuticals (Basel). 2009 Dec 15;2(3):194-205. doi: 10.3390/ph2030194, PMID 27713233.
119. Hector KL, Lagisz M, Nakagawa S. The effect of resveratrol on longevity across species: a meta-analysis. Biol Lett. 2012 Oct 23;8(5):790-3. doi: 10.1098/rsbl.2012.0316, PMID 22718956.
120. Pallauf K, Rimbach G, Rupp PM, Chin D, Wolf IM. Resveratrol and lifespan in model organisms. Curr Med Chem. 2016 Dec 23;23(41):4639-80. doi: 10.2174/0929867323666161024151233, PMID 27781945.
121. Song J, Liu L, Hao K, Mao S, Tang Y, Tong X. Resveratrol elongates the lifespan and improves antioxidant activity in the silkworm Bombyx mori. J Pharm Anal. 2021 Jun;11(3):374-82. doi: 10.1016/j.jpha.2020.06.005, PMID 34277125.
122. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer. 2002 Mar 26;86(5):774-8. doi: 10.1038/sj.bjc.6600197, PMID 11875742.
123. Gambini J, Ingles M, Olaso G, Lopez Grueso R, Bonet Costa V, Gimeno Mallench L. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability and biological effects in animal models and humans. Oxid Med Cell Longev. 2015;2015:837042. doi: 10.1155/2015/837042, PMID 26221416.
Published
How to Cite
Issue
Section
Copyright (c) 2026 LALIT P. DEWALKAR
This work is licensed under a Creative Commons Attribution 4.0 International License.